S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AVXL Anavex Life Sciences Corporation

8.64

0.00 (0.00%)

Pre Market

Last Updated: 20:35:59

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Anavex Life Sciences Charts.

Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Anavex Life Sciences Charts.

Anavex Life Sciences Corporation News

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Monday 27 January 2025 (1 week ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 18 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Wednesday 15 January 2025 (3 weeks ago) • GlobeNewswire Inc.

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Monday 13 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 6 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 24 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 24 December 2024 (1 month ago) • Edgar (US Regulatory)

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Monday 23 December 2024 (1 month ago) • GlobeNewswire Inc.

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Monday 23 December 2024 (1 month ago) • GlobeNewswire Inc.

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Monday 16 December 2024 (2 months ago) • GlobeNewswire Inc.

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Monday 9 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 7 December 2024 (2 months ago) • Edgar (US Regulatory)

More Anavex Life Sciences Corporation News Articles

Invesco QQQ Trust Series 1

Commonwealth Bank Of Aus...

AUD vs US Dollar

Verizon Communications

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions